Study Details
Tocilizumab or TCQ: A Study Drug for Pediatric Patients with COVID-19
(IRB#: IRB_00150759)
Tocilizumab or TCQ is a study drug to help pediatric patients hospitalized with COVID-19. Research is needed to learn if it is safe and effective for these patients. The information we gain may aid futures patients.
- All genders
- All Ages
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: All Ages
Volunteers: Volunteers with special conditions
Location: In Person
COVID-19 Study
Inclusion Criteria
- Must be hospitalized with COVID-19
- 18 years old or younger
Exclusion Criteria
- Known allergic reaction to the study medicine
- Tuberculosis
- Pregnant
Will I be paid for my time?
Yes
IRB#: IRB_00150759
PI: Kevin Watt
Department: PEDIATRICS
Approval Date: 2022-06-22 06:00:00
Study Categories: COVID-19 Studies
Specialties: Infectious Diseases